Modulation of Cortical Brain Activity During Attentional Control (NCT06748976) | Clinical Trial Compass
RecruitingNot Applicable
Modulation of Cortical Brain Activity During Attentional Control
Argentina35 participantsStarted 2025-07-01
Plain-language summary
The goal of this study is to determine whether an open-loop sham neurofeedback system can effectively modulate EEG alpha rhythms, which are associated with attentional control. The main questions it aims to answer are:
Does positive sham neurofeedback lead to a decrease in relative EEG alpha power compared to a control condition without feedback?
Researchers will compare the effects of positive and negative sham-neurofeedback conditions to a control condition without feedback to assess the system's impact on alpha rhythm modulation. Participants will:
Experience three conditions (positive sham-neurofeedback, negative sham-neurofeedback, and no feedback) within a virtual reality environment.
Undergo EEG recordings to measure changes in alpha power as a marker of attentional resource allocation.
Provide written informed consent and complete the study following ethical guidelines.
This study seeks to explore the potential of open-loop feedback systems to enhance attentional control by modulating alpha rhythm.
Who can participate
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults aged between 18 and 60 years.
* Normal or corrected vision.
* Ability to provide written informed consent.
Exclusion Criteria:
* Diagnosed with photosensitive epilepsy.
* Significant hearing loss or diagnosed hearing impairment.
* Current psychiatric illness or disorder.
* History of migraines or chronic headaches.
* History of substance or alcohol abuse.
* Currently pregnant.
* Discomfort with using a virtual reality headset, assessed during a pilot session.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Relative alpha power
Timeframe: Immediately after intervention
Trial details
NCT IDNCT06748976
SponsorNational Council of Scientific and Technical Research, Argentina